Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 4:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 55 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Plasmapheresis Clear all
Recruiting No phase listed Observational

Biorepository and Registry for Plasma Exchange Patients

NCT05004493
View directory record Official record
Conditions
Antibody-mediated Rejection, NMO Spectrum Disorder, TTP, CIDP
Interventions
Not listed
Lead sponsor
Charles M Knudson
Other
Eligibility
12 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2040
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 19, 2025 · Synced Sep 7, 2026, 4:36 PM EDT
Completed No phase listed Observational

Plasmapheresis of Anthrax-Vaccinated Subjects for Production of Anthrax Immune Globulin

NCT00031291
View directory record Official record
Conditions
Anthrax
Interventions
Anthrax Immune Globulin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 7, 2026, 4:36 PM EDT
Not listed No phase listed Observational

Impact of Therapeutic Plasma Exchange on RNA Biomarker Expression Levels in Alzheimer's Patients

NCT06079827
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Not listed
Lead sponsor
MaxWell Clinic, PLC
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Timeline
2022 – 2025
U.S. locations
1
States / cities
Brentwood, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Sep 7, 2026, 4:36 PM EDT
Recruiting Phase 3 Interventional

Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)

NCT07100990
View directory record Official record
Conditions
Optic Neuritis, Myelitis, Myelitis, Transverse
Interventions
High-dose corticosteroids (HDCS), High-dose corticosteroids (HDCS) and PLEX
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
33
States / cities
Scottsdale, Arizona • Loma Linda, California • Sacramento, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 7, 2026, 4:36 PM EDT
Terminated Phase 3 Interventional

Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP)

NCT00411801
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura (TTP)
Interventions
Uniplas, Cryosupernatant plasma
Biological
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Centreville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Sep 7, 2026, 4:36 PM EDT
Terminated Phase 3 Interventional Results available

Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP)

NCT00799773
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura
Interventions
Rituximab, Plasma exchange, Corticosteroids
Drug · Procedure
Lead sponsor
Carelon Research
Other
Eligibility
12 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
23
States / cities
Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2013 · Synced Sep 7, 2026, 4:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

IMPACT (Improving Plasma Collection) Clinical Trial

NCT04320823
View directory record Official record
Conditions
Apheresis Related Hypotension
Interventions
Updated Plasma Collection Feature, Current Plasma Collection Approach
Device
Lead sponsor
Haemonetics Corporation
Industry
Eligibility
18 Years to 66 Years
Enrollment
3,443 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
3
States / cities
Wichita, Kansas • Charlotte, North Carolina • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Sep 7, 2026, 4:36 PM EDT
Completed Phase 3 Interventional Results available

Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura

NCT05468320
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura
Interventions
Caplacizumab, Corticosteroids, anti-CD20 antibody
Drug · Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Birmingham, Alabama • Baltimore, Maryland • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Sep 7, 2026, 4:36 PM EDT
Completed No phase listed Observational

Evaluation of Complication Rates Using Filter vs. Centrifuge and Heparin vs. Citrate Anticoagulation

NCT04351438
View directory record Official record
Conditions
Therapeutic Plasma Exchange, Anticoagulant Therapy
Interventions
Active Comparator: centrifuge TPE with citrate, Active Comparator: Filter TPE with heparin, Active comparator: Filter TPE with citrate
Device · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
0 Years to 24 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Sep 7, 2026, 4:36 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Apheresis and Specimen Collection Procedures to Obtain Plasma, Peripheral Blood Mononuclear Cells (PBMCs) and Other Specimens for Research Studies

NCT00067054
View directory record Official record
Conditions
Sample Collection
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2003
U.S. locations
2
States / cities
Bethesda, Maryland • Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 7, 2026, 4:36 PM EDT
Terminated Phase 2 Interventional Results available

Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection

NCT04343755
View directory record Official record
Conditions
COVID-19
Interventions
Convalescent Plasma
Biological
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 17, 2023 · Synced Sep 7, 2026, 4:36 PM EDT
Not yet recruiting No phase listed Observational

Pharmacokinetic Study of Therapeutic Plasma Exchange

NCT07756242
View directory record Official record
Conditions
Immune-related Adverse Event
Interventions
Spectra Optia Apheresis System
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 7, 2026, 4:36 PM EDT
Completed Not applicable Interventional Results available

A Randomized Trial Examining Plasma Exchange Using the Becton Dickinson (BD) Catheter In an Outpatient Apheresis Unit

NCT04253756
View directory record Official record
Conditions
Plasma Exchange
Interventions
20-gauge BD Nexiva Diffusics
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2022 · Synced Sep 7, 2026, 4:36 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Permeability Factor in Focal Segmental Glomerulosclerosis

NCT00007475
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis
Interventions
Plasma exchange, Cyclophosphamide
Procedure · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Sep 7, 2026, 4:36 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral Sclerosis

NCT02872142
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Albutein 5%, Plasma Exchange
Biological · Procedure
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
19 Years to 69 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Sep 7, 2026, 4:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Safety of Autologous Lyophilized Plasma Versus Fresh Frozen Plasma in Healthy Volunteers

NCT00968487
View directory record Official record
Conditions
Healthy
Interventions
Lyophilized Plasma, Fresh Frozen Plasma
Biological · Other
Lead sponsor
HemCon Medical Technologies, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 23, 2012 · Synced Sep 7, 2026, 4:36 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device

NCT01210716
View directory record Official record
Conditions
Autoimmune Diseases, Renal Disorders, Hematologic Disorders, Oncologic Disorders
Interventions
Therapeutic plasma exchange
Device
Lead sponsor
Fenwal, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
New Haven, Connecticut • Rochester, Minnesota • Charlottesville, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2013 · Synced Sep 7, 2026, 4:36 PM EDT
Terminated No phase listed Observational

Apheresis to Obtain Plasma or White Blood Cells for Laboratory Studies

NCT00001349
View directory record Official record
Conditions
Leukopheresis, Plasmapheresis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Sep 7, 2026, 4:36 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease

NCT01561053
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Albumin 5%, Albumin 20%, Immunoglobulin
Biological
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
55 Years to 85 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
22
States / cities
Sacramento, California • Denver, Colorado • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Sep 7, 2026, 4:36 PM EDT
Terminated Phase 1 Interventional

A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74

NCT06597656
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
delandistrogene moxeparvovec, Plasmapheresis
Genetic · Procedure
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
4 Years to 8 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Gainesville, Florida • St Louis, Missouri • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Sep 7, 2026, 4:36 PM EDT
Not yet recruiting Phase 2 Interventional

Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis

NCT07674745
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Therapeutic Plasma Exchange, Rituximab, Intravenous immunoglobulin, Treatment as Usual
Other · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years to 85 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
9
States / cities
Birmingham, Alabama • Chicago, Illinois • Kansas City, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 7, 2026, 4:36 PM EDT
Completed Phase 2 Interventional Results available

Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS

NCT04374149
View directory record Official record
Conditions
Cytokine Release Syndrome, COVID19
Interventions
Therapeutic Plasma Exchange, Ruxolitinib
Procedure · Drug
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
12 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Sep 7, 2026, 4:36 PM EDT
Terminated No phase listed Observational

Octaplas Adult TTP Trial

NCT01938404
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura
Interventions
Octaplas, Standard Plasma
Biological · Drug
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
2
States / cities
Manhasset, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2019 · Synced Sep 7, 2026, 4:36 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use

NCT00001846
View directory record Official record
Conditions
Blood Donors, Research Subjects, Apheresis
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 7, 2026, 4:36 PM EDT